Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
C-Reactive Protein
Chemotherapy, Cancer, Regional Perfusion
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ adverse effects
Humans
Hyperthermia, Induced
/ adverse effects
Hyperthermic Intraperitoneal Chemotherapy
Kinetics
Peritoneal Neoplasms
/ drug therapy
Postoperative Complications
/ epidemiology
Prognosis
Retrospective Studies
C-reactive protein
HIPEC
Peritoneal carcinomatosis
Postoperative complications
Prediction
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
26 Nov 2020
26 Nov 2020
Historique:
received:
09
03
2020
accepted:
09
11
2020
entrez:
27
11
2020
pubmed:
28
11
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Relatively high morbidity rates are reported after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, early predictors of complications after CRS plus HIPEC have not been identified. The aim of this study was to evaluate the predictive role of early postoperative serum C-reactive protein (CRP) level (Day 2-4) for the detection of post-operative complications. We performed a retrospective study including 94 patients treated with complete CRS (R1) and HIPEC for PC from various primary origins (2011-2016). Post-operative complications were recorded. The values for postoperative inflammatory markers (white blood cells [WBC] and platelet counts, CRP) were compared between the different groups. CRP on post-operative days 2-4 was significantly higher in patients with than without complications (124 mg/L vs 46 mg/L; p < 0.0001) and higher in those with more major complications (162 mg/L vs 80 mg/L; p < 0.0012). WBC and platelet counts showed no difference within 5 days postoperatively. CRP levels, and kinetics mainly, between post-operative day 2 and 4, are decisive predictive markers of early and late post-operative complications after CRS plus HIPEC. The presence of post-operative complications should be suspected in patients with a high CRP mean, and a plateau level (days 2-4).
Sections du résumé
BACKGROUND
BACKGROUND
Relatively high morbidity rates are reported after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, early predictors of complications after CRS plus HIPEC have not been identified. The aim of this study was to evaluate the predictive role of early postoperative serum C-reactive protein (CRP) level (Day 2-4) for the detection of post-operative complications.
PATIENTS AND METHODS
METHODS
We performed a retrospective study including 94 patients treated with complete CRS (R1) and HIPEC for PC from various primary origins (2011-2016). Post-operative complications were recorded. The values for postoperative inflammatory markers (white blood cells [WBC] and platelet counts, CRP) were compared between the different groups.
RESULTS
RESULTS
CRP on post-operative days 2-4 was significantly higher in patients with than without complications (124 mg/L vs 46 mg/L; p < 0.0001) and higher in those with more major complications (162 mg/L vs 80 mg/L; p < 0.0012). WBC and platelet counts showed no difference within 5 days postoperatively.
CONCLUSION
CONCLUSIONS
CRP levels, and kinetics mainly, between post-operative day 2 and 4, are decisive predictive markers of early and late post-operative complications after CRS plus HIPEC. The presence of post-operative complications should be suspected in patients with a high CRP mean, and a plateau level (days 2-4).
Identifiants
pubmed: 33243287
doi: 10.1186/s12957-020-02081-6
pii: 10.1186/s12957-020-02081-6
pmc: PMC7694318
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
311Références
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Int J Colorectal Dis. 2007 Dec;22(12):1499-507
pubmed: 17639424
Surgery. 2008 Jan;143(1):20-8
pubmed: 18154929
World J Surg. 2010 Jan;34(1):70-8
pubmed: 19760317
Medicina (Kaunas). 2016;52(1):1-10
pubmed: 26987494
Int J Surg. 2016 Aug;32:65-70
pubmed: 27353848
J Surg Res. 2017 Apr;210:261-268
pubmed: 28457337
J Clin Oncol. 2012 Jan 20;30(3):263-7
pubmed: 22162570
Ann Surg. 2012 Aug;256(2):334-41
pubmed: 22580946
Int J Surg. 2012;10(2):87-91
pubmed: 22222182
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
World J Surg. 1999 Jan;23(1):23-9
pubmed: 9841759
Int J Gynecol Cancer. 2016 Jun;26(5):912-7
pubmed: 27051055
Surg Oncol. 2018 Dec;27(4):657-662
pubmed: 30449489
Ann Surg Oncol. 2015 Apr;22(4):1332-40
pubmed: 25234021
Gastroenterol Clin Biol. 2006 Oct;30(10):1200-4
pubmed: 17075479
Eur J Surg Oncol. 2003 Feb;29(1):69-73
pubmed: 12559080
J Gastrointest Oncol. 2016 Aug;7(4):523-9
pubmed: 27563441